Literature DB >> 27301942

Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.

Rafal Meus1, Maksim Son1, Dorota Sobczyk1, Anetta Undas2.   

Abstract

BACKGROUND AND
PURPOSE: We hypothesized that formation of left atrial appendage (LAA) thrombi of unknown origin is associated with altered fibrin clot properties and blood hypercoagulability.
METHODS: In a case-control study, we investigated 32 patients with a history of LAA thrombus after successful anticoagulant treatment versus 32 control subjects matched for age, sex, and diabetes mellitus. All subjects had previous ischemic stroke, transient ischemic attack, or migraine associated with patent foramen ovale. Patients with documented atrial fibrillation were excluded. We determined plasma fibrin clot permeability, fibrinolytic efficiency, thrombin generation, platelet and endothelial markers. Stroke or transient ischemic attack were assessed during a median follow-up of 74 (range 19-98) months.
RESULTS: Compared with controls, patients with LAA thrombus more frequently were smokers (43.8% versus 18.8%) and had 20% prolonged clot lysis time, lower plasminogen (-14%), and higher plasminogen activator inhibitor-1 (+17%), thrombin-antithrombin complexes (+17%), CD40 ligand (+30%), P-selectin (+29%), and von Willebrand factor (+30%, all P<0.05). Occurrence of LAA thrombus was predicted by von Willebrand factor (β=0.038, P=0.004), plasminogen (β=-0.048, P=0.01), plasminogen activator inhibitor-1 (β=-0.161, P=0.03), and clot permeability (β=-1.076, P=0.03). During follow-up, cerebrovascular events occurred in 10 (33.33%) of the 30 available patients in the LAA thrombus group, including 7 (23.3%) with recurrent LAA thrombus and 4 (13.33%) with documented atrial fibrillation. Recurrent LAA thrombus was associated with lower baseline Ks and higher thrombin generation, fibrinogen, plasminogen activator inhibitor-1, and soluble CD40 ligand (all P<0.05).
CONCLUSIONS: Prothrombotic blood alterations could be involved in the LAA thrombus formation in patients without documented atrial fibrillation and are associated with increased risk of stroke or transient ischemic attack during follow-up.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; fibrin; left atrial appendage; stroke; thrombus

Mesh:

Substances:

Year:  2016        PMID: 27301942     DOI: 10.1161/STROKEAHA.116.012856

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

1.  Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.

Authors:  Paweł T Matusik; Barbara Małecka; Jacek Lelakowski; Anetta Undas
Journal:  Clin Res Cardiol       Date:  2019-07-06       Impact factor: 5.460

2.  Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation.

Authors:  Dimpi Patel; Amir Darki; Debra Hoppensteadt; Iman Darwish; Mushabbar Syed; Yevgeniy Brailovsky; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

3.  Left Ventricular Ejection Fraction Can Predict Atrial Thrombosis Even in Non-High-Risk Individuals with Atrial Fibrillation.

Authors:  Petra Angebrandt Belošević; Anton Šmalcelj; Nikola Kos; Krešimir Kordić; Karlo Golubić
Journal:  J Clin Med       Date:  2022-07-07       Impact factor: 4.964

4.  Difference in left atrial appendage remodeling between diabetic and nondiabetic patients with atrial fibrillation.

Authors:  Chaim Yosefy; Marina Pery; Roman Nevzorov; Xavier Piltz; Azriel Osherov; Jamal Jafari; Ronen Beeri; Enrique Gallego-Colon; Aner Daum; Vladimir Khalameizer
Journal:  Clin Cardiol       Date:  2019-11-22       Impact factor: 2.882

5.  Diabetes induces remodeling of the left atrial appendage independently of atrial fibrillation in a rodent model of type-2 diabetes.

Authors:  Or Yosefy; Barucha Sharon; Chana Yagil; Mark Shlapoberski; Alejandro Livoff; Ilana Novitski; Ronen Beeri; Yoram Yagil; Chaim Yosefy
Journal:  Cardiovasc Diabetol       Date:  2021-07-23       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.